Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Sham-controlled, Comparative Study of SI-6603 in Subjects With Lumbar Disc Herniation (Phase 3)

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-blind, Sham-controlled, Comparative Study of SI-6603 in Subjects With Lumbar Disc Herniation (Phase 3)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Condoliase (Primary)
  • Indications Intervertebral disc displacement
  • Focus Registrational; Therapeutic Use
  • Acronyms Discovery 6603
  • Sponsors Seikagaku Corporation

    • Most Recent Events

    • 25 Sep 2024 Results published in a Ferring Pharmaceuticals Media Release
    • 25 Sep 2024 According to a Ferring Pharmaceuticals Media Release, data from two Phase 3 trials in the U.S. and one in Japan, evaluating efficacy and safety of SI-6603 being studied for the treatment of radicular leg pain associated with lumbar disc herniation (LDH). The podium presentation at the North American Spine Society's (NASS) Annual Meeting
    • 09 Sep 2024 According to a Ferring Pharmaceuticals Media Release, Seikagaku and Ferring entered into a license agreement for SI-6603 in August 2016. Ferring plans to commercialize the product in the United States, upon FDA approval.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top